Q&A

Friday, March 11, 2022

11:48 AM – 12:00 PM CST

Location: Coronado

Moderator(s)

Fabian M. Johnston, MD, MHS

Associate Professor of Surgery
Johns Hopkins University
Baltimore, MD, United States

Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Deepa Magge, MD, FACS

Assistant Professor of Surgery
Vanderbilt University Medical Center
Nashville, TN, United States

Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Presenter(s)

Willemien van Driel, MD, PhD

gyne-oncologist
Antoni van Leeuwenhoek, Nederlands Kanker Instituut
Amsterdam, Netherlands

Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Olivier Glehen, MD, PhD

Professor
Centre Hopsitalier Lyon Sud, France

Disclosure: Gamida (Individual(s) Involved: Self): Consultant

Participants should be aware of the following financial/non-financial relationships:

Fabian M. Johnston, MD, MHS: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Deepa Magge, MD, FACS: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Willemien van Driel, MD, PhD: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Olivier Glehen, MD, PhD: Gamida (Individual(s) Involved: Self): Consultant

Participants will be able 1. To provide an overview of evidence of CRS/HIPEC in ovarian and colorectal malignancies
2.To address limitations of study designs and better define important take-aways from these landmark randomized controlled trials

Olivier Glehen- Role of HIPEC in colorectal peritoneal metastases
Willemien J van Driel- Role of HIPEC in ovarian cancer

CME